In vitro method for predicting mortality risk in patients suffering from shock
AssigneesFundació Institut D'Investigació En CièNcies De La Salut Germans Trias I Pujol, Fundació Centre De Regulació GenòMica, Universitat Pompeu Fabra
InventorsEduard Sabidó Aguade, Eva Borràs Ramirez, Ferran Rueda Sobella, Antonio Bayés Genis, Oriol Iborra Egea, Cosme García García
Life of this patent
Estimating the term…
Abstract
In vitro method for predicting mortality risk in patients suffering from shock. The present invention refers to the medical field. Particularly, it refers to an in vitro method for predicting mortality risk among patients suffering from shock, which comprises determining in a biological sample obtained from the patient the concentration level of specific proteins.
Claims15
A method of treating a human patient determined to have a mortality risk and who is suffering from cardiogenic shock, or who has suffered from cardiogenic shock, comprising:
- treating the human patient having the mortality risk with a cardiogenic shock treatment, wherein the mortality risk has been determined by steps comprising:
- a) obtaining a biological sample from the human patient, wherein the biological sample is a serum or plasma sample, or a combination thereof;
- b) analyzing concentration levels of B2MG protein in a sample prepared from the biological sample, wherein the sample is analyzed by:
- i) an enzyme-linked immunosorbent assay;
- or
- ii) a mass spectrometry assay;
- c) comparing the concentration levels of the B2MG protein as analyzed in step b) relative to levels of B2MG protein in a biological sample from a control survivor human patient suffering from cardiogenic shock as analyzed by the same assay;
- and
- d) determining the mortality risk of the human patient, wherein an increased level of the B2MG with respect to the concentration level determined in the control survivor human patient suffering from cardiogenic shock is an indication of mortality risk.
A method of treating a human patient having a mortality risk and who is suffering from cardiogenic shock, or has suffered from cardiogenic shock, comprising:
- treating the human patient having the mortality risk with a cardiogenic shock treatment, wherein the cardiogenic shock treatment comprises treatment with a ventricular assist device, revascularization, hemodynamic stabilization, treatment of multiorgan system dysfunction, administration of anti-arrhythmic agents, administration of synchronized cardioversion, administration of positive inotropic agents, administration of mechanical circulatory support, treatment using extracorporeal life support systems, heart transplantation, or any combination thereof;
- and wherein the mortality risk has been determined by steps comprising:
- a) obtaining a biological sample from the human patient, wherein the biological sample is a serum or plasma sample, or a combination thereof;
- b) analyzing concentration levels of B2MG protein in the biological sample by:
- i) an enzyme-linked immunosorbent assay;
- or ii) a mass spectrometry assay;
- c) comparing the concentration levels of the B2MG protein as analyzed in step b) relative to levels of B2MG protein in a biological sample from a control survivor human patient suffering from cardiogenic shock as analyzed by the same assay;
- and
- d) determining the mortality risk, wherein an increased level of the B2MG with respect to the concentration level determined in the control survivor human patient suffering from cardiogenic shock is an indication of mortality risk.
Dependencies are inferred from the claim text.